Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods.

IF 3.7 2区医学 Q2 INFECTIOUS DISEASES Current HIV/AIDS Reports Pub Date : 2024-12-07 DOI:10.1007/s11904-024-00715-y

Casey Bishopp, Zoe Mungai-Barris, Elmari Briedenhann, Emily Donaldson, Elizabeth Irungu, Katie Schwartz

{"title":"Understanding the Drivers of CAB PrEP Uptake and Use among Women in sub-Saharan Africa to Build Demand for New PrEP Methods.","authors":"Casey Bishopp, Zoe Mungai-Barris, Elmari Briedenhann, Emily Donaldson, Elizabeth Irungu, Katie Schwartz","doi":"10.1007/s11904-024-00715-y","DOIUrl":null,"url":null,"abstract":"Purpose of review: As injectable cabotegravir for pre-exposure prophylaxis (CAB PrEP) is introduced in sub-Saharan Africa, it is important to understand how behavioral drivers may influence women's decisions around whether or not to use it.Recent findings: Facilitating factors include prior familiarity with injections and the perceived efficacy of CAB PrEP, while barriers include a fear or dislike of needles and negative attitudes held by community members and influencers. Further research is needed to fully understand behavioral factors affecting African women's CAB PrEP use. HIV prevention policymakers, practitioners, advocates, and clients are optimistic about CAB PrEP, predicting that this long-acting method will be popular among women in sub-Saharan Africa. However, women may also face barriers to use. Knowledge of behavioral facilitators and barriers can enhance the adaptation or development of HIV prevention communication and demand generation strategies that support informed decision-making in a multi-method market.","PeriodicalId":10930,"journal":{"name":"Current HIV/AIDS Reports","volume":"22 1","pages":"7"},"PeriodicalIF":3.7000,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11625055/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV/AIDS Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11904-024-00715-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: As injectable cabotegravir for pre-exposure prophylaxis (CAB PrEP) is introduced in sub-Saharan Africa, it is important to understand how behavioral drivers may influence women's decisions around whether or not to use it.

Recent findings: Facilitating factors include prior familiarity with injections and the perceived efficacy of CAB PrEP, while barriers include a fear or dislike of needles and negative attitudes held by community members and influencers. Further research is needed to fully understand behavioral factors affecting African women's CAB PrEP use. HIV prevention policymakers, practitioners, advocates, and clients are optimistic about CAB PrEP, predicting that this long-acting method will be popular among women in sub-Saharan Africa. However, women may also face barriers to use. Knowledge of behavioral facilitators and barriers can enhance the adaptation or development of HIV prevention communication and demand generation strategies that support informed decision-making in a multi-method market.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

了解撒哈拉以南非洲妇女CAB PrEP接受和使用的驱动因素，以建立对新PrEP方法的需求。

综述目的：随着可注射的卡波特韦暴露前预防（CAB PrEP）在撒哈拉以南非洲的推广，了解行为驱动因素如何影响妇女是否使用它的决定是很重要的。最近的发现：促进因素包括先前对注射的熟悉程度和CAB PrEP的有效性，而障碍包括对针头的恐惧或厌恶以及社区成员和影响者所持的消极态度。需要进一步的研究来充分了解影响非洲妇女使用CAB PrEP的行为因素。艾滋病预防政策制定者、从业者、倡导者和客户对CAB PrEP持乐观态度，预测这种长效方法将在撒哈拉以南非洲的妇女中流行。然而，女性也可能面临使用障碍。对行为促进因素和障碍的了解可以加强艾滋病毒预防沟通和需求产生战略的适应或发展，从而支持在多方法市场中做出知情决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current HIV/AIDS Reports INFECTIOUS DISEASES-

CiteScore

8.10

自引率

2.20%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of HIV/AIDS. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as antiretroviral therapies, behavioral aspects of management, and metabolic complications and comorbidity. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.